Hims & Hers Health/$HIMS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Hims & Hers Health

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Ticker

$HIMS
Sector

Primary listing

NYSE

Employees

1,637

HIMS Metrics

BasicAdvanced
$12B
69.84
$0.78
2.14
-

What the Analysts think about HIMS

Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.

Bulls say / Bears say

Hims & Hers plans to offer Eli Lilly's Zepbound (tirzepatide) and generic versions of liraglutide, expanding its weight-loss lineup as regulations tighten on compounding. (Reuters)
In Q1 2025, Hims & Hers posted 111% year-over-year revenue growth, with GLP-1 weight-loss drug sales making up $200 million of its $1.5 billion 2024 revenue, highlighting strong demand. (Reuters)
On September 10, 2025, Hims & Hers launched personalized low testosterone treatments and plans to roll out Kyzatrex and injectable therapies in 2026, marking a strategic expansion into men's health. (Reuters)
On June 23, 2025, Novo Nordisk ended its Wegovy distribution partnership with Hims & Hers, leading HIMS shares to fall over 30%, showing the company's exposure to partner disputes. (Reuters)
In May 2025, Hims & Hers reduced its workforce by 4% after the FDA banned compounded weight-loss drug copies, with its shares dropping 14%, underscoring regulatory risks. (Reuters)
Analysts have raised concerns about the legitimacy of Hims & Hers' "personalized" semaglutide dosages and warn that ongoing compounding could trigger legal issues and limit insurer partnerships. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

HIMS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HIMS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HIMS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs